18:34 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

Apellis pauses Phase III trials after single lot of APL-2 causes inflammation

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) voluntarily paused dosing in Phase III trials of intravitreal APL-2 to treat geographic atrophy due to eight reported cases of non-infectious inflammation in patients treated from a single manufacturing lot of...
18:48 , Oct 18, 2018 |  BC Extra  |  Clinical News

Apellis pauses Phase III trials after single lot of APL-2 causes inflammation

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) lost $2.85 (17%) to $13.86 on Thursday after it voluntarily paused dosing in Phase III trials of intravitreal APL-2 to treat geographic atrophy due to eight reported cases of non-infectious inflammation...
19:36 , Apr 20, 2018 |  Completed Offerings  |  Completed Offerings

Apellis raises $140.3M in follow-on

Autoimmune company Apellis Pharmaceuticals Inc. (NASDAQ:APLS) raised $140.3 million late on April 18 through the sale of 5.5 million shares at $25.50 in a follow-on underwritten by Citigroup, J.P. Morgan and Cowen. The price is...
17:58 , Apr 20, 2018 |  Clinical Results  |  Clinical Results

Apellis reports additional Phase Ib data for C3 inhibitor in PNH

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported data from eight evaluable patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received Soliris eculizumab in the open-label, New Zealand Phase Ib PADDOCK trial showing that once-daily 270...
20:27 , Apr 19, 2018 |  BC Extra  |  Financial News

Apellis raises $140.3M in follow-on

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) raised $140.3 million late Wednesday through the sale of 5.5 million shares at $25.50 in a follow-on underwritten by Citigroup, J.P. Morgan and Cowen. The price is a 15% discount to...
20:35 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Apellis reports 18-month Phase II data for GA candidate

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported 18-month data from the Phase II FILLY trial to treat geographic atrophy showing that APL-2 for 12 months maintained significant reductions in lesion growth at six months after stopping treatment....
22:56 , Feb 22, 2018 |  BC Extra  |  Clinical News

Apellis reports 18-month data for GA candidate

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported 18-month data from the Phase II FILLY trial to treat geographic atrophy showing that APL-2 for 12 months maintained significant reductions in lesion growth at six months after stopping treatment....
20:46 , Nov 10, 2017 |  BC Week In Review  |  Financial News

Apellis prices $150M IPO

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) raised $150 million after market hours on Nov. 8 through the sale of 10.7 million shares at $14 in an IPO underwritten by Citigroup, JPMorgan and Evercore. The price is at...
17:40 , Nov 9, 2017 |  BC Extra  |  Financial News

Apellis prices $150M IPO

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) raised $150 million after market hours Wednesday through the sale of 10.7 million shares at $14 in an IPO underwritten by Citigroup, JPMorgan and Evercore. The price is at the midpoint...
19:30 , Oct 13, 2017 |  BioCentury  |  Product Development

Eyeing complement data

Clinical studies of four complement inhibitors in patients with age-related macular degeneration suggest the best target in the pathway may be complement 3 . However, differences between study populations and methods and durations of treatment...